|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||15.89 - 16.55|
|52 Week Range||11.23 - 23.99|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.50|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution on June 28, 2021. “Werewolf’s inclusion in the Russell 2000® index marks an important milestone that re
General Atlantic initiated a large position in U.K. biopharmaceutical firm Centessa Pharmaceuticals. Magnetar Capital disclosed a stake in furniture maker Knoll.